Where Tech Meets Bio

Could Anthropic Disrupt the Techbio Companies Built for Pharma/Biotech?

AlSO: The Numbers Behind China's Biopharma Ascent

Jul 2 • Andrii Buvailo, PhD

29

14

5

June 2026

My Seven Health Tech Observations From HLTH Europe 2026 Event

AI is moving from writing clinical notes to checking them. "Human-in-the-loop" is becoming a product, not a footnote. Nearly everyone is racing to own…

Jun 26 • Andrii Buvailo, PhD

15

1

Is the Future of AI Drug Discovery Hybrid?

Some field notes from the cutting edge of modern bioinformatics (CoFold Summit and Free Energy Workshop, both held recently in Barcelona, Spain).

Jun 1 • Andrii Buvailo, PhD

27

2

May 2026

Is “Rescuing Failed Drugs with AI” a Category Now?

Inside the growing bet that AI can find the patients pharma's failed trials missed...

May 21 • Andrii Buvailo, PhD and Roman Kasianov

34

4

5

April 2026

From Biohacking to Healthcare: The Growing Pains of the Longevity Industry

Part I: A tour of the therapeutic strategies targeting the hallmarks of aging—from cellular reprogramming to senolytics, mTOR inhibitors, and immune…

Apr 16 • Louise von Stechow and BiopharmaTrend

26

2

7

Weekly Tech+Bio #81: AI Agents at the Cancer Conference

AI-pharma deals track toward a 12x increase in five years, Life Biosciences takes cell reprogramming to Phase 1, and Jeito closes Europe's largest…

Apr 14 • Roman Kasianov, Andrii Buvailo, PhD, and BiopharmaTrend

16

2

Weekly Tech+Bio #80: Organoids on Artemis II

Anthropic's $400M AI biotech acqui-hire, CRO stocks reprice, new EMA draft, and pharma's spring acquisition spree

Apr 6 • Roman Kasianov, Andrii Buvailo, PhD, and BiopharmaTrend

12

4

4

Everyone is Launching AI Agents. What's Being Deployed?

A check-in on biopharma's agentic AI buildout

Apr 4 • Roman Kasianov and Andrii Buvailo, PhD

22

3

4

March 2026

Weekly Tech+Bio Highlights #79: A Pharma Factory in an Egg

Lilly's $2.75B generative chemistry deal and why AI research might be locked into 'hypernormal' science

Mar 30 • Roman Kasianov and Andrii Buvailo, PhD

9

3

Weekly Tech+Bio Highlights #78: AI Agents Rush In

Roche and Lilly scale up pharma's biggest AI supercomputers, a billion-dollar startup unveils its virtual cell, and agents are everywhere

Mar 23 • Roman Kasianov, Andrii Buvailo, PhD, and BiopharmaTrend

15

3

Weekly Tech+Bio Highlights #77: AI-Guided mRNA Vaccine Shrinks Dog's Cancer

Google's AI doctor passes its first clinic test, China's first take-home BCI, OpenFold3 goes fully open, and arXiv is going independent

Mar 16 • BiopharmaTrend, Roman Kasianov, and Andrii Buvailo, PhD

10

2

Simulating the Control Arm: Virtual Patients at the Trial Bottleneck

Digital twins promise smaller, faster trials, and the regulatory scaffolding is forming. But there’s still a validation gap.

Mar 14 • BiopharmaTrend

22

4